新華製藥(000756.SZ):阿茲夫定新增臨牀試驗為抗新型冠狀病毒適應症、其試驗結果尚未公開發布
格隆匯5月11日丨新華製藥(000756.SZ)發佈風險提示性公吿,此前披露的公司與河南真實生物科技有限公司(“真實生物”)簽署的戰略性合作協議,是基於公司戰略發展的需要及對行業市場前景的判斷,存在一定的市場風險,合作項目未來所產生的經營效益存在不確定性。
需要特別提示的是:真實生物所持有的阿茲夫定是抗艾滋病藥物,於2021年獲得國家藥監局批准,目前新增臨牀試驗為抗新型冠狀病毒適應症。真實生物治療此適應症的臨牀試驗結果尚未公開發布,此適應症尚未獲得國家藥監局批准。
公司將根據合作事宜的進展,按照《深圳證券交易所股票上市規則》和《公司章程》等相關規定,履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.